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2. Abbreviations 
LGG - Low grade glioma 
2016 CNS WHO - 2016 World Health Organization Classification of Tumours in the Central 
Nervous System 
PCV - Procarbazine-lomustine (CCNU)-vincristine 
KPS - Karnofsky Performance Status 
CRF - Case Report Form  
RANO - Response Assessment in Neuro Oncology 
FLAIR - Fluid-attenuated inversion recovery 
fMRI - functional magnetic resonance imaging  
nTMS - Navigated transcranial magnet stimulation  
DTI - diffusion tensor imaging 
IDH – Isocitrate dehydrogenase 
FISH – Fluorescence in situ hybridization  
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3. Abstract 
Introduction: Lower-grade glioma (WHO grade II and III) are malignant brain tumours that 
grow infiltratively and eventually transform into glioblastoma (grade IV) resulting in death. A 
negative prognostic marker following lower-grade glioma diagnosis is old age, but its 
covariance with other known prognostic factors and tumour biology remains elusive. In 
addition, impaired outcome following glioma diagnosis in the elderly may also be due to 
“ageism”, where older patients receive suboptimal care.  
Objective: Study differences in tumour characteristics, symptomatology, patterns of care and 
outcome in older and younger patients with lower-grade glioma.  
Methods: We studied 69 patients (>50 years, older cohort) and 90 patients (18-50 years, 
younger cohort) with histopathological diagnosis of lower-grade glioma between 2010-2016 
at Sahlgrenska University Hospital.  
Results: Older patients presented more often with cognitive deficits (21.7% vs 6.7 %, p= 
0.005) and focal deficits (37.7% vs 22.2%, p=0.033). They were more often biopsied and less 
often underwent resection compared to young patients (37.7% vs 14.4%, p=0.001) and their 
disease-specific survival were significantly impaired (p<0.001). Our preliminary findings 
suggests differences in the patterns of underlying mutations between the groups, with more 
IDH-wildtype lower-grade gliomas in the older group (p=0.011). 
Conclusion: The impaired survival in elderly patients were probable due to a combination of 
negative prognostic factors, but where tumour biology presumably were of major importance. 
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4. Introduction 
4.1 Classification 
Glioma is a wide term for all types of tumours arising from glial cells, the non-neural 
supportive cells of the nervous system. Diffuse infiltrative gliomas are malignant tumours that 
share histological and genetic traits, more specifically they encompass the subtypes 
astrocytoma and oligodendroglioma. These tumours are histologically graded based on their 
degree of malignancy from II-IV. Grade II represents a low-grade glioma (LGG), grade III an 
intermediate anaplastic tumor and grade IV represents the most malignant tumour, also called 
glioblastoma. The new 2016 World Health Organization Classification of Tumours in the 
Central Nervous System (2016 CNS WHO) has now for the first time also introduced 
molecular markers to the classification system that further subdivides the tumours into three 
new groups based on their IDH-status (isocitrate dehydrogenase-status). These three new 
groups are IDH-mutation with 1p19q-codeletion in both chromosomes (canonical 
oligodendroglioma), IDH-mutation with intact 1p19q chromosomes (IDH-mutated 
astrocytoma) and IDH-wildtype (absence of any IDH-mutation) (1). Figure 1 below presents 
a flowchart of the new glioma classification. 
Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are metabolic enzymes involved in the 
catalyzation of isocitrate. The role of IDH1 and IDH2 genes in glioma oncogenesis remains 
elusive but mutations in these genes often coexist with other genetic alterations such as 1p19q 
codeletions, TP53-mutations and ATRX loss. Recent research seem to indicate different 
pathophysiological processes for the development of IDH-mutated glioma and IDH-wildtype 
glioma (2).  
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Figure 1. Classification of diffuse glioma according to 2016 CNS WHO. Three separate 
tumours can be identified, Diffuse astrocytoma IDH-wildtype (absence of any IDH-mutation), 
Diffuse astrocytoma IDH-mutant (IDH-mutation with intact 1p19q chromosomes) and 
Oligodendroglioma (IDH-mutation with 1p19q-codeletion).  
IDH-status are assessed using immunohistochemistry but a complete assessment may also 
require genetic sequencing. 1p19q co-deletion status are assessed using fluorescence in situ 
hybridization (FISH) if either of IDH1 or IDH2 are found to be mutated on the 
immunohistochemistry or genetic sequencing. 
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The new integrated grouping system based on both phenotypical and molecular traits also 
group tumours into prognostic relevant subgroups where also treatment may differ. The 
presence of molecular markers such as IDH-mutation with 1p19q-codeletion and IDH-
mutation with intact 1p19q chromosomes (i.e. IDH mutated astrocytoma) have in previous 
studies been linked to a more favorable prognosis (1). On the other hand the absence of an 
IDH-mutation, referred to as IDH-wildtype astrocytoma, has been linked to a negative 
outcome (1, 3). Following the introduction of molecular markers, the new term “lower-grade 
glioma” were introduced to encompass grade II and III tumours with distinct molecular 
patterns of IDH and 1p19q-status (3, 4). This complete redrawing of how tumours are 
classified have lead to the clear separation of oligodendroglioma and astrocytoma based on 
the occurrence or absence of IDH-mutations and 1p19-codeletion, and this has also lead to the 
disappearance of oligoastrocytomas, previously a common sub-entity in the 2007 WHO 
classification system (1, 5). 
The natural history of lower-grade glioma is the inevitably transformation into a more 
malignant glioblastoma, referred to as a secondary glioblastoma. This tumour is usually 
different than the primary glioblastoma that develops de novo and is associated with elderly 
people and a shorter median overall survival. (1) However, survival after transformation to a 
secondary glioblastoma is as poor as for primary glioblastomas (6, 7). With the introduction 
of molecular markers it is apparent that most secondary gliomas are IDH mutated, while 
primary glioblastomas are IDH wild-type (8).  
4.2 Epidemiology 
Glioma is the most common type of malignant primary brain tumour (9), and range 
approximately as 10th most common cancer in Sweden (10). On the other hand, malignant 
gliomas take more life years than any other cancer at the individual level (11).  Data from the 
Swedish Cancer Registry show that the average incidence rate of LGG in Sweden is 
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approximately 1/100,000 and for higher grade glioma about 5/100,000 (10). LGG often affect 
young adults with an incidence peak at age 30-44, although it is important to remember that 
LGG is also present in the elderly at fairly equal numbers. Anaplastic and glioblastoma 
tumours are more common in the elderly compared to the young and peak around an age of 
65-79 (9, 10).  
4.3 Clinical manifestations 
In LGG, the most common presenting symptom at diagnosis is an epileptic seizure. Focal and 
cognitive deficits are more common in high-grade glioma (12). It is less common with 
headache as a presenting symptom, and headache rarely presents as the sole symptom, instead 
it is accompanied by other neurological deficits (13). An increased use of radiological 
imaging has also lead to a rising number of cases diagnosed as incidentalomas. Common 
reasons for finding a glioma incidentally are trauma and headache not related to tumor mass 
effect (14) 
4.4 Diagnosis and additional testing 
For lower-grade gliomas MRI is the radiological gold standard (15). The diffuse gliomas has a 
highly infiltrative growth within the brain and has a diffuse border in relation to the normal 
brain matter. Different MRI relaxation techniques (T1, T2) alongside Fluid-attenuated 
inversion recovery (FLAIR) are utilized to identify the dimensions of the tumor bulk. 
Contrast-enhancement (gadolinium-based) can be used to differentiate low-grade and high-
grade glioma, where presence of enhancement normally indicative of a more vascularized and 
malignant tumour, but oligodendrogliomas quite frequently harbor non-specific mild contrast 
enhancement (16). On the other hand, almost a third of non-enhancing lesions typical for the 
low-grade glioma WHO grade II are in fact high-grade gliomas (17). 
Low-grade glioma typically exhibits a hyperintense signal on the T2/FLAIR-image without 
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contrast enhancement on the T1-image. A typical glioblastoma presents with an irregular 
contrast enhancement, usually alongside its borders in a ring-formed manner. Glioblastoma 
also tends to exhibit a surrounding edema and a necrotic or hemorrhaging core. Glioblastoma 
may also be multifocal, displaying contrast enhancement in different areas of the brain.  Low-
grade glioma tumours undergoing malignant transformation usually exhibit radiographic 
transformation features on MRI prior to manifestation of worsening of symptoms (18).  
A case description of typical radiological features are presented below in figure 2.  
Many glioma patients are extensively investigated pre- and postoperatively with regard to 
differential diagnosis and brain function. Additional testing procedures can include;  
functional magnetic resonance imaging (fMRI) and navigated transcranial magnet stimulation 
(nTMS) for mapping the motor cortex and language center (lateralization), tractography for 
visualization of nerve tracts using diffusion tensor imaging (DTI) (19) and 
neuropsychological evaluation for assessing cognitive functions. 
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Figure 2. Case description: 2010) Fifty year old female patient presenting with seizures. T2-
weighted MRI shows a high signaling tumour with a moderately diffuse growth pattern in the 
left temporal and frontal lobe. T1-image with contrast did not exhibit any enhancement. 
Finding indicative of a low-grade glioma, histopathological diagnosis following resection 
was later confirmed to be a grade II astrocytoma. 2015) Same patient five years later, T1 
contrast-enhanced image shows multifocal ring-formed contrast-enhancement in the left 
temporal lobe. Finding indicative of a malignant transformation to a glioblastoma. 
 
 
4.5 Neurosurgical and adjuvant treatment 
Treatment consists of surgical resection of as much tumour tissue as possible without causing 
permanent and disabling injury. In low-grade glioma, a strategy favoring early radical 
resection compared to watchful waiting was associated with a clear survival advantage in a 
study from 2012 (20). Depending on tumour location and extension, biopsy is however the 
only reasonable option for some patients. Following histopathological diagnosis, radiation 
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therapy and/or chemotherapy with temozolomide or PCV (Procarbazine-lomustine-
vincristine) can be of value in high-risk patients. A number of clinical trials on the subject of 
adjuvant treatment in grade II and grade III glioma have been conducted and treatment today 
is determined in a complex manner by carefully weighing together tumour characteristics, 
radiological features, performance status, disease progression and patient characteristics (21-
25). 
4.6 Prognostic factors 
Established prognostic factors for glioma are tumour type, tumor size, age and Karnofsky 
performance status (KPS) (9, 26). KPS is a functional rating scale that measures symptom 
burden and how much the disease impacts normal activities in everyday life. The ten-degree 
scale ranges from 100% (no signs of disease or symptoms) to 0% (dead). A complete 
definition of KPS scoring criteria are presented in the appendices section’s first page. 
The overall 5-year relative survival varies significantly with tumour histology, grade II 
oligodendroglioma has a 5-year survival rate at 74.1% while anaplastic astrocytoma has a 5-
year survival rate of just 10.8% (27). Prognosis based on molecular status show that IDH-
wildtype carry the highest risk while IDH-mutations without 1p19q codeletion have an 
intermediate risk and IDH-mutations with 1p19q codeletion carry the lowest risk (3, 4). Old 
age has been shown to relate to a poor prognosis in glioma patients, but few studies have been 
devoted to this topic (9, 26, 28). A 2008 paper by Chang et al studying prognostic factors in 
hemispheric low-grade glioma found an age cut-off at patient age > 50 years as a negative 
prognostic factor (29). 
4.7 Medical significance 
Survival following glioma seems dependent on age (9, 26, 28). A recently published register 
based study from Sweden demonstrated that elderly patients with LGG are more often only 
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biopsied, and when resected they receive more complications and they survive shorter. One 
possible explanation could be that the tumours are radically different between the old and 
young, another possibility might be that the allocation of resources are different between the 
groups, i.e “ageism” (30).  
Brain tumours are one of few tumours that are common among young people and low-grade 
glioma typically present in younger adults. This study will seek to highlight further 
knowledge about the presentation, underlying biology and treatment related factors with 
special focus on the elderly LGG patients.   
 
4. Aim and Research questions 
This study seeks to evaluate how tumour biology, symptomatology, patterns of care and 
clinical results differ in two patient groups; elderly and younger patients with “lower-grade 
glioma” that have undergone a neurosurgical procedure. Our hypothesis was that older people 
present with different tumour characteristics and perhaps as a consequence of this are treated 
differently than younger (e.g. more biopsies). Further, we hypothesize that older age is a 
negative prognostic factor. We intend to shed light on whether a negative outcome is due to 
widely different tumours or less aggressive therapy for comparable tumours. 
4.1 Specific research questions 
1. How do tumour biology differ in the two age groups?  
2. What preoperative symptoms did younger and elderly patients present with? 
3. What treatment and additional testing procedures were offered to the two groups?   
4. How do the presence of surgical complications differ in the two groups? 
5. Is the overall survival rate lower for elderly people?  
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5. Materials and Methods 
5.1 Study design 
This retrospective observational study includes patients at Sahlgrenska University hospital 
who underwent a biopsy or a neurosurgical resection for lower-grade glioma between 2010-
2016. A list of patients undergoing surgery for lower-grade glioma were identified from the 
neurosurgical records and later supplemented with information about histopathology from the 
pathology department at Sahlgrenska University hospital. Inclusion criteria were a grade II 
and grade III glioma that were either an astrocytoma, oligodendroglioma or an 
oligoastrocytoma according to the WHO 2007 classification system. Exclusion criteria were 
patients < 18 years of age, all glioma of infratentorial origin and grade II and III glioma with a 
typical MRI finding of a glioblastoma (i.e sampling bias).  
 
5.2 Study Population 
192 patients were initially identified and 159 met the final inclusion criteria. A flow-chart of 
excluded patients is presented in the appendices section.   
Mean age at diagnosis was 47.5 years. Males represented 58.5% of all glioma patients. The 
two subgroups analyzed were: older patients with age >50 (N= 69) and younger patients aged 
18-50 (N= 90). 
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5.3 Data collection 
Clinical, pathological and radiological data was collected from the patients medical records 
using a standardized Case-Report-Form (CRF). Information was collected about age, sex, 
tumour characteristics, preoperative symptoms, functional rating scale at time of diagnosis 
(Karnofsky Performance status), medical testing procedures, type of surgery, number of 
surgeries, adjuvant treatment, complications and radiological progression. See appendix for 
the CRF.  
Information about preoperative tumor volume was measured using the open source software 
3D slicer.  
Information about tumour markers were collected from the medical records to the extent that 
they were available. 28 tissue sample specimens were also retested for molecular markers at 
the Sahlgrenska Cancer Center and our intention is to get the whole dataset classified for 
molecular markers in the near future. Data concerning death was obtained from the Swedish 
national death registry. The end of follow-up in this study was set to January 1st 2017.  
5.4 Definitions 
Primary surgery was defined as neurosurgical resection or biopsy following tumour diagnosis 
on MRI. As done by others, patients undergoing biopsy followed by resection less than 3 
months later were classified as having a resection as their primary surgery (20). First repeated 
surgery was defined as the next neurosurgical resection following the primary surgery. Of the 
patients undergoing a repeated surgery, 24 patients did so due to progression in their disease 
(tumour recurrence), but five patients underwent reoperation prior to progression due to 
residual tumour mass on the postoperative MRI. 
 
A definitive glioma diagnosis can only be obtained after histopathological examination 
following biopsy or surgery. If a patient who had already been given a histopathological 
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diagnosis later underwent a new biopsy or surgery less than 3 months afterwards and then 
received a different histopathological diagnosis (e.g. now grade III instead of II), than this 
second diagnosis would be considered the real primary diagnosis and the first diagnosis was 
considered due to a sampling error (e.g. caused by biopsy on the edge of the tumour). A 
patient who underwent a new biopsy or surgery more than three months afterwards and 
received for instance a diagnosis of a higher-grade gliomas was considered to have undergone 
a malignant transformation.  
Clinical progression following surgery was assessed using the RANO-criteria (Response 
Assessment in Neuro-Oncology) (31). The first criteria was patients who developed new 
lesions or had an increase of their contrast enhancement on their follow-up MRI, these 
patients were considered to have undergone a radiological malignant transformation. The 
second criterion was patients who had a 25% increase of non-enhancing lesions on their MRI. 
The third criterion was a clinical deterioration that could only be explained by the tumour. 
Progression/transformation was assessed radiologically by continuously comparing the 
follow-up MRI with baseline-MRI after resection or best-response MRI following treatment.  
The changes on the MRI or the clinical deterioration were not to be attributable to “pseudo 
transformation” (effects from radiation or chemotherapy) or a significant change in 
corticosteroid usage.  
General complications were assessed using the classification system introduced by Landriel 
Ibanez et al (32). In this paper, the authors define complications as “deviation from normal 
postoperative outcome within 30 days” and complications are then graded (I-IV) based on the 
severity of the condition and therapy used for treating complications. In addition, new 
neurological deficits following surgery were registered. 
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5.5 Statistics 
SPSS, version 25.0 (Chicago, IL, USA) was used for statistical analyzes. Alpha-level of 0.05 
was used for assessing statistically significant differences. Pearson’s chi-squared test was 
used for testing association between categorical variables. Mann-Whitney U-test were used 
for assessing association between groups when the outcome variable was continuous, but not 
normally distributed. Kaplan-Meier plot analysis was used for comparing survival between 
the two groups and curves were compared using the log-rank test. Cox-regression models 
were used for comparing how different possible predictors affected survival.  
 
6. Ethics 
Patient data was kept de-identified at a safe location within Sahlgrenska University Hospital. 
Approval from the Regional ethics board was obtained prior to study initiation.  
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7. Results 
7.1 Demographics and tumour characteristics 
Within the younger group, 90 patients (56.6%) were identified and the mean age at diagnosis 
was 36.7 years (SD 8.6 years). The older group included 69 patients (43.4%) and the mean 
age at diagnosis was 61.6 years (SD 6.6 years). Males were slightly overrepresented in both 
groups (62.3% in old and 58.4% in young group).  
The total number of grade II (N=81) and grade III (N=78) tumours were distributed somewhat 
surprisingly, with grade II tumours being proportionally more frequent within the old group 
(p=0.028). There were no significant differences in tumour histology (table 1). 
We were able to retrieve molecular markers in 70 patients, thus in 89 patients we could not 
evaluate molecular markers. IDH-wildtype was more common in the old group (N=10, 34.5% 
vs N=4, 9.8%, p=0.011).  Preoperative tumour volume was found to vary greatly between 
individual patients. However, there was no significant difference in preoperative median 
tumour volume between the two age groups, young patients had a median tumour volume of 
70.3 cm3 compared to 88.8 cm3 in old patients (p=0.130).  A full description of demographic 
features and tumour characteristics are presented in Table 1. 
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Table 1. Demographics and tumour characteristics after primary surgery 
 18-50 
N=90 (56.6%) 
>50 
N=69 (43.3%) 
P-value 
Male sex, N (%) 50 (58.4) 43 (62.3)  
Mean age at diagnosis (SD)  
 
36.7 (8.6) 
 
61.6 (6.6) 
 
 
    
Grade II, N=81 39 (43.3) 42 (60.9)  
0.028 Grade III, N=78 51 (56.7) 27 (39.1) 
Astrocytoma Grade II, N (%) 25 (27.8) 28 (40.6) 0.09 
Astrocytoma Grade III, N (%) 29 (32.2) 16 (23.2) 0.210 
Oligoastrocytoma II, N (%) 9 (10.0) 7 (10.1) 0.976 
Oligoastrocytoma III, N (%) 16 (17.8) 6 (8.7) 0.100 
Oligodendroglioma II, N (%) 5 (5.6) 7 (10.1) 0.278 
Oligodendroglioma III, N (%) 6 (6.7) 5 (7.2) 0.886 
Molecular markers N, (%)    
IDH-wildtype  
(high risk) 
4/41 (9.8) 10/29 (34.5) 0.011 
IDH-mutation - Non 1p19q-codeletion 
(intermediate risk) 
11/41 (26.8) 6/29 (20.7) 0.490 
IDH -mutation – 1p19q-codeletion 
(low risk) 
23/41 (56.1) 12/29 (41.4) 0.155 
IDH-mutation  
(not tested for 1p19q-codeletion) 
3/41 (7.3) 1/29 (3.4) N/A 
Tumor markers not assessed 49  40   
Tumour size    
Median tumour size in cm3  
(Range) 
52.5 cm3 
(3.1 – 373.4 cm3) 
67.0 cm3 
(2.4 – 464.2 cm3) 
0.130 
Missing, (N=16)  (7)  (9)  
% represents percentage within each group, e.g. there were 25 patients with grade II astrocytomas within 
the young group(N=90) representing 27.8 % of all tumours in the young. 
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7.2 Presenting symptoms 
Seizure was the most common presenting symptom in both the younger (72.2%) and the older 
(63.8%). Seizure as the sole presenting symptom was significantly more frequent in the young 
group with 55.6% of patients presenting with no other symptoms than seizure compared to 
34.8% in the old group (p=0.009). Headache as a presenting symptom was also significantly 
more common in the young group (p=0.008). Headache usually presented alongside other 
symptoms and headache as the only presenting symptom was very rare in both groups (N=7). 
The presence of cognitive changes at diagnosis was significantly more common in the old 
group compared to the young (p=0.005). Focal deficit symptoms were also significantly more 
frequent in the old group (p=0.033). No difference was observed in the symptom duration or 
performance status at time of diagnosis. Detailed description of presenting symptoms is 
presented in Table 2. 
Table 2. Presenting symptoms 
 18-50 
(N=90) 
>50 
(N=69) 
P-value 
Asymptomatic/Incidentaloma, N (%) 6 (6.7) 7 (10.1) 0.43 
Seizure, N (%) 65 (72.2) 44 (63.8) 0.26 
Seizure only, N (%) 50 (55.6) 24 (34.8) 0.009 
Headache, N (%) 28 (31.1) 9 (13.0) 0.008 
Cognitive changes, N (%) 6 (6.7) 15 (21.7) 0.005 
Focal deficit symptoms, N (%) 20 (22.2) 26 (37.7) 0.033 
Motor deficit 11 (12.2) 14 (20.3) 0.17 
Language deficit 6 (6.7) 8 (11.6) 0.28 
Visual deficit 3 (3.3) 4 (5.8) N/A 
Other symptoms*, N (%) 7 (7.8) 11 (15.9) 0.11 
Symptom duration, N (%) 
< 30 week 
 
> 30 weeks 
(Missing/Asymptomatic, N=13) 
 
67 (74.4) 
 
17 (18.9) 
 
48 (70.0) 
 
14 (20.3) 
0.69 
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Karnofsky performance status, N (%) 
100 
90 
80 
70 or less 
 
 
21 (23.3) 
30 (33.3) 
22 (24.4) 
17 (18.9) 
 
19 (27.0) 
21 (30.4) 
14 (20.2) 
15 (21.7) 
 
0.84 
*Other symptoms included sensory disturbances(N=10), dizziness(N=9),  Syncope(N=1), 
Dysphagia(N=1). 
 
 
7.3 Treatment and additional testing 
Old patients more often underwent biopsy only procedures (37.7%) instead of resection 
compared to the young group (14.4%), with a statistically significant difference (p=0.001).   
Mapping procedures (awake mapping or motor mapping asleep) during resection were less 
often offered to the older group (p= 0.025). Only one (2.3%) patient in the old group 
underwent an awake mapping procedure compared to 12 patients (15.6%) in the young group. 
Mean age for patients undergoing awake mapping procedures were 36.8 years. There was no 
other significant difference with regard to intraoperative tools used during resection between 
the age groups. The old group also seemed to be offered less additional testing procedures but 
there was only a significant difference between the groups in regard to neuropsychology 
assessments pre-/postoperatively. Table 3 presents an overview of the neurosurgical treatment 
and testing procedures offered to the two groups.   
Table 3. Primary neurosurgical treatment and additional testing procedures 
 18-50 
(N= 90) 
>50 
(N=69) 
P-value 
Biopsy only, N (%) 13 (14.4) 26 (37.7)  
0.001 Resection*, N (%) 77 (85.6) 43 (62.3) 
Tools used intraoperatively, N (%)    
Ultrasound 39 (50.6) 21 (48.8) 0.849 
Neuronavigation 55 (71.4) 26 (60.5) 0.219 
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5-ALA 5 (9.1) 2 (4.7) N/A 
Mapping procedure  
-Awake mapping 
-Motor mapping asleep 
15 (19.5) 
12 (15.6) 
3 (3.9) 
2 (4.7) 
1 (2.3) 
1 (2.3) 
0.025 
Additional testing procedures, N (%)     
Navigated transcranial 
magnetic stimulation 
14 (16.0) 7 (10.1) 0.318 
Speech therapist assessment 5 (5.6) 5 (7.2) N/A 
Neuropsychology 
assessment 
33 (36.7) 15 (21.7) 0.042 
Other test 
(Tractography, fMRI) 
12(13.3) 5 (7.2) 0.218 
* indicates resection as the primary neurosurgical procedure or biopsy followed by resection 
within 3 months.  
 
There were 46 older patients (66.6%) and 55 (61.1%) of younger patients who underwent 
treatment with chemotherapy (p=0.471). However when broken down in to treatment in 
respect to tumour grade in the groups, we could observe that chemotherapy were more 
frequently administered to old patients (57.1%) with grade II tumours than young patients 
(30.8%) with grade II tumours (p=0.017).  No significant difference was observed between 
the two groups when comparing the administration of chemotherapy in grade III tumours. 
However treatment with PCV for grade III tumours was more common in the young group, 
especially PCV-treatment subsequent to radiotherapy.  
In a similar manner we observed no difference between overall treatment with radiotherapy 
when looking at both grade II and III tumours. However elderly patients with grade II 
tumours received more radiotherapy compared to the young group (p=0.028) and young 
patients with grade III tumours received more radiotherapy compared to the old group 
(p=0.020). Regarding the modality of radiotherapy offered, no difference was observed in the 
administration of photon therapy and proton therapy between the two groups.  
The mean absorbed radiation dose administered to the patients was higher in the young group 
 22 
compared to the old (p=0.037).  However, we identified five cases of outliers in the sample 
who represented patients who had either been forced to terminate radiotherapy prematurely 
(N=1) or had been given a modified low-dosage treatment (N=4) of less than 34 Gy due to 
disease related circumstances. Four out of these outliers were elderly patients and when they 
were removed from the analysis there was no significant difference in administered 
radiotherapy dose between the older (median 54.0 Gy, range 30.0-60.0 ) and the young (59.4 
Gy, range 40.0-66.0). Table 4 outlines an overview of adjuvant treatment. 
 
Table 4. Adjuvant treatment offered to the patients before any repeated surgery 
 18-50 
(Grade II, N=39) 
(Grade III, N=51) 
>50 
(Grade II, N=42) 
(Grade III, N=27) 
P-value 
Chemotherapy, N (%) 
 
Chemotherapy, Grade II 
Temozolomide 
PCV* 
 
 
Chemotherapy, Grade III 
Temozolomide 
PCV* 
55 (61.1%) 
 
12 (30.8) 
10 
2 
 
 
43 (84.3) 
34 
9 
46 (66.6%) 
 
24 (57.1) 
22 
2 
 
 
22 (81.5) 
21 
1 
0.471 
 
0.017 
 
 
 
 
0.749 
Radiation therapy, N (%) 
 
Radiotherapy, Grade II 
 
Radiotherapy Grade III 
 
Radiation modality, N (%)y 
Photon therapy 
Proton therapy 
56 (62.2) 
 
13 (33.3) 
 
43 (84.3) 
 
51 (56.6) 
5 (5.6) 
39 (56.5) 
 
21 (50.0) 
 
18 (66.7) 
 
36 (52.2) 
3 (4.3) 
0.560 
 
0.028 
 
0.020 
 
0.573 
0.730 
Accumulated Radiation dose, Median Gy 
(Range) 
59.4 Gy  
(40.0-66.0) 
54.0 Gy  
(30.0 -60.0) 
0.037 
*Procarbazine-lomustine (CCNU)-vincristine 
 23 
 
7.4 Postoperative complications 
Elderly patients suffered more general complications within 30 days following resection than 
the young, however we observed no significant difference between the two patient groups. 
There was an overweight of complications requiring intervention with general anaesthesia in 
the younger group, this was mainly due to six cases of postoperative intracranial infection 
requiring reoperation with partial removal of the skull in this group compared to one case in 
the old group. Of all the 34 general complications, 30 of them occurred after a resection and 
just three complications (two cases of venous thromboembolism and one case of refractory 
status epilepticus resulting in death within 1 day) were observed after biopsies. All general 
complications are listed below in table 5. 
Regarding postoperative outcome (new focal neurological complication following resection), 
language and motor complications were the most frequent in both groups. Again, there was no 
difference between groups.  There was no significant difference in the frequency of 
permanent neurological complications. Table 5 provide a detailed overview of complications. 
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Table 5. Postoperative complications (resections only) 
 18-50 
(N=77) 
>50 
(N=43) 
P-value 
General complications within 30 days following 
resection*, N (%) 
17 (22.1) 10 (23.3) 0.882 
Grade Ia, no drugs 1 4 N/A 
Grade Ib, drugs 6 4 N/A 
Grade IIa, intervention without 
general anesthesia 
1 1 N/A 
Grade IIb, intervention with 
general anesthesia 
8 1 N/A 
Grade IIIa, Single organ failure, 
Intensive care unit 
1 0 N/A 
Neurological outcome following resection, N (%)    
Motor complications 
Permanent(>3 months) 
12 (15.6) 
 6 (7.8) 
10 (23.3) 
4 (9.3) 
0.298 
Language complications 
Permanent(>3 months) 
16 (20.8) 
8 (10.4) 
11 (25.7) 
8 (18.6) 
0.546 
Cognitive complications 
Permanent(>3 months) 
5 (6.5) 
2 (2.6) 
6 (14.0) 
4 (9.3) 
N/A 
Visual complications 
Permanent(>3 months) 
5 (6.5) 
1 (1.3) 
6 (14.0) 
3 (7.0) 
N/A 
Cranial nerve complications 
Permanent(>3 months) 
1 (1.3) 
0 
0 
0 
N/A 
Worsening of seizure 1 (1.3) 2 (4.6) N/A 
Postoperative rehabilitation following resection 13 (16.9) 6 (14.0) 0.673 
* General complications were: postoperative intracranial infection requiring reoperation (N=7), Brain 
edema requiring new or adjusted dose corticosteroids (N=3), Subdural hematoma (N=2), Venous 
thromboembolism (N=2), Scalp abscess (N=2), Scalp infection (N=2), Intracerebral hematoma (N=2), 
Hemorrhagic infarction (N=1), Asystole (N=1), CSF-rhinorrhea requiring reoperation (N=1), 
Extracranial edema (N=1), Extracranial hematoma (N=1), Urinary tract infection (N=1), Caliciviridae 
infection (N=1), Postoperative fever of unknown origin (N=1), Surgically induced first-time epileptic 
seizure (N=1), Miscarriage during pregnancy (N=1). 
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7.5 Outcome 
RANO-criteria (criteria 1 to 3) was used for assessing clinical progression. Significantly more 
patients in the older group were found to have progressed or undergone a malignant 
transformation compared to the younger group (p<0.001). In the older group, 66.7% of the 
patients met one of the RANO-criteria whereas only 36.7% did so in the younger group.  In 
both groups, malignant transformation (criteria 1) on follow-up MRI was the most frequently 
met criteria. We found that 55 patients (69.6%) of patients who met any RANO-criteria had 
died compared to 30.4% who were still alive as of end of follow-up (p<0.001). Median 
survival was just eight months in the patients who met any RANO-criteria.  
Despite that elderly patients progressed more frequently in their disease, only 10.1% of old 
patients were offered a repeated surgery compared to 24.4% in the young group (p=0.021). 
Table 6 details the specifics about progression and repeated treatment.  
Table 4. Clinical progression and repeated treatment 
 18-50 
(N=90) 
>50 
(N=69) 
P-value 
Clinical progression (RANO-criteria, 1-3), N (%) 33 (36.6) 46 (66.7) <0.001 
1. Any new lesion or increase of contrast 
enhancement on MRI 
(malignant transformation) 
23 30 0.017 
2. T2 or FLAIR MRI with a 25% increase of 
non-enhancing lesion 
7 7 0.602 
3. Clinical deterioration 3 9 0.022 
Repeated resection, N (%) 22 (24.4) 7 (10.1) 0.021 
Chemotherapy following repeated surgery, N (%) 18 (81.8) 5 (71.4) 0,554 
Radiation following repeated surgery, N (%) 14 (63.6) 4 (57.1) 0,757 
Deceased due to tumor during follow-up, N (%) 20 (22.2) 36 (52.2) <0.001 
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38 elderly patients had died at the end of follow-up compared to 21 patients in the young 
group. Three patients (two in the old group and one in the young group) died during the 
follow-up period from diseases unrelated to their glioma diagnosis and before reaching any of 
the RANO-criteria for progression. The cause of death in these instances were gastric cancer, 
aspiration pneumonia in a patient who was suspected of having developed a motor neuron 
disease and sepsis brought on by a limb infection. These patients were censored in the 
survival analysis, meaning that the disease-specific survival was 22.2 % in the young group 
and 52.2% in the old group during follow-up.  
Disease-specific survival over time between the groups was assessed using a Kaplan-Meier 
analysis plot (log-rank p<0.001) and are presented in figure 3. Twenty months after surgery, 
60% of patients in the older group were still alive versus 90% of patients in the younger 
group. Forty months following surgery only 38% of patients in the old group were still alive 
compared to 82% in the young group. The median decease related survival was 29 months in 
the older group (95 % CI 16.3-35.7) while median survival was not reached for the younger 
group. When comparing survival over time stratified and looking only on patients who 
underwent a resection, the difference between the two groups was smaller but still significant 
(log-rank p<0.001, figure 4). 
Survival was dependent on the type of neurosurgical treatment. Figure 5 outlines a 
comparison of survival between all patients who underwent resection versus patients who 
were only biopsied.  
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.  
Figure 3. Survival following surgery in months between the two age groups. 18-50y (N=90), 
>50y (N=69). Log-rank p-value <0.001 
 
Figure 4. Survival between age groups following surgery in patients who underwent 
resection. 18-50 (N=77), >50 (N=43). Log-rank p <0.001. 
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Figure 5. Comparison of survival following resection(N=120) versus biopsy(N=39) in all 
patients. Log-rank p-value < 0.001. 
 
Survival varied with presenting symptoms. Patients who presented with only seizure had a 
survival advantage compared to patients who also presented with other symptoms (figure 6). 
In a similar manner, patients presenting with Karnofsky performance status of 100 or 90 had a 
better survival compared to patients who had a low Karnofsky performance status of 80 or 
less (figure 7).  
We observed no difference in survival between grade II and grade III tumours when looking 
at all patients, log-rank p-value = 0.462 (figure 8). When classifying patients into 3 risk 
categories based on their IDH-status (high-risk IDH-wildtype, intermediate risk IDH-mutation 
non 1p19q-codeletion, low-risk IDH-mutation 1p19q codeletion) we observed a significant 
survival disadvantage in the IDH-wildtype group. Unfortunately, 89 patients did not have 
their tumour markers assessed yet and were missing in the analysis. See Figure 9.  
We observed no significant difference in survival when comparing survival between age 
groups, looking only at patients with IDH-mutations. See figure 10. 
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Figure 6. Survival in relationship to presenting symptoms in all patients. Log-rank p-value < 
0.001. Only seizure (N=74), Other symptoms (N=72). Missing=Incidentaloma (N=13).  
 
 
 
Figure 7. Survival at different Karnofsky performance status in all patients. Log-rank p-value 
=.,001. Karnofsky 90-100 (N=91), Karnofsky 80 or less (N=68).  
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Figure 8. Survival in grade II (N=81), grade III (N=78) tumours. Log-rank p-value =0.462.  
 
Figure 9. Survival according to IDH-status. Log-rank p-value < 0,001.  
IDH-mutation 1p19q-codeletion (N=35) 
IDH-mutation non 1p19q-codeletion (N=17).  
IDH-wildtype (N=14). 
Missing=93 (89 tumour markers not assessed, 4 IDH-mutations with unknown 1p19q-status). 
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Figure 10. Survival according to IDH-mutant status, IDH-wildtype excluded. Log-rank p-
value =0,372. 
IDH-mutation 1p19q (N=35) 
IDH-mutation non 1p19q (N=17) 
IDH-mutation non 1p19q (N=4) 
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We used a Cox multivariable model to study survival in the different age groups when also 
including other underlying predictors. The first model was adjusted for sex, tumour grade (II 
or III), Karnofsky performance status (KPS 100-90 vs KPS <90) and preoperative tumour size 
in ml. KPS, grade and age were all significant predictors while sex and tumour size were not 
significant. Survival in the older group was significantly impaired compared to the younger 
group when adjusted for these underlying predictors (p < 0.001, see figure 11).  
Figure 11. Survival adjusted for sex, grade, KPS and tumour size. 
Missing = 16, did not have their tumour size measured.   
 
The second Cox-regression model analyzed survival between age groups adjusted for sex, 
tumour grade, KPS and IDH-status (high-risk IDH-wildtype or low-intermediate risk IDH-
mutation) and is presented in figure 12. The model still demonstrated that older age had a 
survival disadvantage compared to the younger group. IDH-wildtype hazard ratio was 25.3 
(95 % CI 4.3 -150.3) compared to having IDH-mutation.  
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Figure 12. Survival between age groups adjusted for sex, tumour grade, KPS and IDH-status. 
High-risk wildtype IDH (N=14).  
Low-intermediate risk IDH-mutation (1p19q codeletion + non 1p19q codeletion) (N=56). 
Missing = tumour markers not assessed (N=89). 
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8. Discussion 
8.1 Main findings 
This study compared tumour biology, presentation, patterns of care and outcome in lower-
grade glioma patients in a younger (18-50) and older (>50) cohort. Neurological deficits were 
more frequent in older patients compared to younger patients. Disease-specific survival was 
significantly lower in the older group compared to the younger group. Elderly patients were 
more often only offered a biopsy procedure, nevertheless patients in the old group still had a 
significantly lower survival than young patients when comparing only for resections. 
Although preliminary, we documented that molecular markers were highly associated with 
age. Somewhat different treatment and tools were provided but we did not find strong 
evidence of “ageism”. The observed differences in treatment related factors might be readily 
explained by differences in tumor characteristics and presentation, although intraoperative 
mapping was perhaps underused in the older group of patients.   
8.2 Tumour characteristics 
Interestingly, patients in the older cohort had more grade II tumours compared to the younger 
cohort and elderly patients should then seemingly have an advantage in tumour biology 
according to the 2007 WHO classification system (5). Still, we found that their survival was 
significantly impaired compared to the younger. Previous studies have observed the problem 
of interobserver variation in traditional diagnosis of lower-grade glioma (33, 34) and the 
clinical implementation of molecular markers can improve this inaccuracy in diagnosis as 
well as lending itself as a more accurate prognostic marker (4). However, in WHO 2016 grade 
is still used and molecular markers is for subgrouping within the group, although this may be 
revised due to the abovementioned problems. We did not have molecular data for all patients 
but our preliminary findings strongly suggests that IDH-wildtype is more common in the 
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older group of lower-grade glioma, something that is in accordance with previous literature 
(35, 36). “The Cancer Genome Atlas” (TCGA) which analyzed 293 patients with lower-grade 
glioma found that molecular markers based on IDH and 1p19q-status are superior to 
histology-based classification and that IDH-wildtype low-grade glioma are more similar to 
glioblastoma with a worse outcome (4). When IDH wildtype tumors were excluded from our 
analysis, the additional impact of age was in fact rather marginal.  
8.3 Presenting symptoms 
Seizure was the most frequently registered presenting symptom in both cohorts, younger 
patients more often presented with only seizures while older patients more often presented 
with cognitive changes and focal deficits. These findings are in accordance with previous 
research into the symptomatology of glioma (13, 29, 30) 
Patients presenting with low symptom burden, that is high functional performance status at 
time of diagnosis, were associated with better survival than those who did not. However there 
was no significant difference in performance status between the old and young group. The 
findings on this are not in line with other works in the literature which link patient age with 
worse functional status (12, 30) but this may be due to a difference in sample with more grade 
II tumours in the older group than reported in other works (12, 15).  
Treatment 
Jakola et al demonstrated that early radical resection correlated with an improved survival 
over a strategy with watchful waiting and biopsy in the treatment of low-grade glioma (20, 
37). Like previous studies, we found that older patients receive less aggressive therapy with 
less resections compared to biopsies (30, 38). However, this study also investigated pre- and 
intraoperative tools used for resection and found that old patients less often undergo resection 
with awake mapping or motor mapping asleep. The surgical use of “intraoperative stimulation 
mapping” (ISM) were assessed in a 2010 metanalysis by De Witt Hamer et al and found that 
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usage of ISM correlates with more extensive resection which in turn is associated with longer 
survival (39). Although this study currently lacks data on anatomical tumour location and 
eloquent tumour localization, our findings of 19.5 % of younger patients undergoing any 
mapping procedure compared to 4.7 % of older patients might suggests an unequal allocation 
of resources between young and old patients. De Witt Hamer et al argues for two scenarios 
where the use of ISM is unfavorable, the first being related to localization and the second 
involving patients who might not benefit from the reduced permanent deficits in 
compensation for increased transitory deficits (39). Old patients with a low functional status 
and an expected shorter survival may fit this second criterion, however this study did not 
identify any significant difference in functional performance status between the age groups. 
 
Other studies have reported the importance of how maximum extent of resection (EOR) and 
minimum residual tumour volume impacts survival in low-grade glioma tough the exact 
dimensions of the EOR required for a meaningful survival advantage remains under debate 
(40-42). Unfortunately, this study did not yet have information about the postoperative extent 
of resection between the age groups. We can however show that patients in the old cohort 
were offered a repeated surgery less often than the young cohort, something that has been 
linked to impaired survival following recurrence in low-grade glioma (43), for high-grade 
glioma there is no consensus in the scientific community on the role of repeated surgery (44).  
 
Adjuvant treatments were investigated as treatment-related factors that might influence 
outcome in the two patient groups. Overall we found no significant difference in the number 
of patients who received chemotherapy or radiation therapy when looking at both grade II and 
III tumours. The difference in adjuvant therapy that emerged when looking at grade II and 
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grade III tumours separately were likely due to different treatment regimens based on tumour 
and patient characteristics in the two age groups (22-24).  
8.4 Complications 
General complications within 30 days of surgery mostly occurred following resection. The 
observed frequency of both general complications and postoperative outcome (focal 
neurological complications) were not found to be significantly different in the older and 
younger group, even when we removed the potential dilution effect of biopsy, analyzing 
resections separately. A recent study found more focal neurological deficits in older (>60 
years) LGG patients undergoing resection compared to young patients (30) and the reason this 
study found an insignificant difference (albeit a general trend towards more focal deficits in 
the old group) may be attributable to a smaller sample size in this study.   
 
8.5 Outcome 
Our survival analysis adjusted for age, KPS, gender and tumour size demonstrated a 
significantly impaired survival in the older group. Worse outcome for elderly patients in this 
study do not seem to be due to different tumour biology according to traditional glioma 
classification or treatment-related factors such as chemotherapy or radiotherapy. However, 
older patients had more IDH-wildtype tumours, and our multivariable model including 
molecular markers reduced the impact of age, albeit older age was still a negative prognostic 
factor. Hence, age seems to offer prognostic data beyond molecular data. Our aim in the 
future is to catalogue all the patient’s molecular data to get a more holistic view of how 
genetic tumor biology is distributed between the groups. We also intend to present a more 
complete reflection of the radiological data with information about tumor location, tumor 
eloquence and extent of resection in the near future.  
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8.6 Strengths and limitations 
The main limitation of this study is the absence of a complete set of molecular markers. The 
recent emergence of molecular profiling in glioma diagnosis is still in its infancy, this meant 
that only 42 patient’s treated between 2010-2016 had their tumours tested. The 
reclassification for the purpose of studies in lower-grade gliomas further added 28 patients 
with molecular information. Another limitation is this study’s lack of radiological data. The 
retrospective nature of this study also represent a major methodological challenge with 
respect to sensitivity for certain measures, interpretation, bias by indication (45).  
A major strength of this study were the reasonable long follow-up that is needed to assess 
clinical outcomes in lower-grade gliomas. Also, we have no loss to follow-up and great 
accessibility of patient’s medical records. Consequently this study has very small amounts of 
missing data. Other strengths of this study included clinical data collection from the medical 
records conducted by the same person (author), design of case-report form prior to retrieval of 
clinical data and mostly an adequate patient population size for statistical analysis (except 
certain sub group analyses).  
This study’s exclusion of tumours with radiographic features of glioblastoma could be seen as 
an example of patient selection bias, however this exclusion likely reduced the effect of 
diagnostic sampling bias when comparing biopsy and resection. 
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8.7 Conclusion 
Older patients with lower-grade glioma presented more often with deficits compared to 
younger patients who more frequently presented with seizure. Complications following 
resection were not associated with patient age. Older patients undergo fewer resections and 
mapping procedures. The reasons for inferior survival in elderly patients is probably 
multifactorial, but where baseline and tumour related factors contribute significantly. 
However, we need more detailed data to conclude on the concern that older patients are 
inappropriately treated with less aggressive surgery compared to their younger counterparts.  
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10. Populärvetenskaplig sammanfattning 
 
Elakartade gliom hos äldre patienter 
Gliom är den vanligaste hjärntumörsformen i Sverige. Den har en mycket hög dödlighet och 
eftersom det är relativt många unga patienter som drabbas så är det den cancerform som 
resulterar i mest förlorade levnadsår. Gliom av grad II och grad III är elakartade tumörer som 
växer infiltrativt och relativt långsamt inuti den normala hjärnvävnaden innan de omvandlas 
till den mest elakartade tumörformen, glioblastom (grad IV) och resulterar i död. 
Symptomen vid  gliom beror på tumörens lokal inuti hjärnan samt dess storlek och växtsätt. 
Ett epileptiskt anfall är det vanligaste symptomet som patienterna debuterar med innan man 
kan upptäcka tumören med hjälp av magnetkameraundersökning. Behandlingen utgörs av 
kirurgi, strålning och cellgifter i olika kombinationer. Behandling syftar till förlänga 
överlevnaden med så bibehållen livskvalitet som möjligt.   
Eftersom gliom är så förknippat med unga patienter så finns det sparsamt med forskning som 
har inriktat sig på gliom hos äldre patienter, denna studie syftade därför till att undersöka hur 
denna aggressiva hjärntumörsform och hur dess behandling skiljer sig mellan unga och äldre 
patienter. 
 
Studien visade att äldre patienter debuterar med andra symptom än yngre patienter, vi såg att 
äldre patienter oftare drabbas av rörelsenedsättningar och kognitiva nedsättningar medans det 
var vanligare med endast epileptiska anfall hos yngre patienter.  
Det framkom en del skillnader i hur de äldre och yngre patienterna behandlades, man såg 
bland annat att äldre patienter mer sällan fick sin tumör bortopererad utan fick istället oftare 
endast genomgå ett vävnadsprov jämfört med yngre patienter. Hos de patienter som fick sin 
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tumör bortopererad såg man också att man använde sig av vakenkirurgiska ingrepp bland 
äldre betydligt mer sällan. Vakenkirurgi är en resursintensiv teknik där patienten är vid 
medvetande och samarbetar med kirurgen som därmed kan skära ut maximal tumörstorlek 
utan att orsaka skador på viktiga delar av hjärnan.  
 
Överlevnaden var betydligt sämre i den äldre gruppen, 20 månader efter patienterna hade 
blivit opererade så levde endast 60% av patienterna i den äldre gruppen jämfört med 90% i 
den yngre gruppen. Beror nu detta på att äldre patienter får sämre vård och opereras sämre? 
Sanningen är troligen mer komplicerade än så och den verkliga orsaken till att äldre patienter 
överlever kortare och handläggs annorlunda beror sannolikt på underliggande skillnader i hur 
tumörerna beter sig biologiskt. Ett av de intressantaste fynden i denna studie var att när man 
testade tumörerna för markörer med underliggande DNA-mutationer så fann man att äldre 
patienter hade mer aggressiva tumörer. Denna studie kunde ännu inte redovisa exakta lokaler 
för tumörerna men en del ledtrådar såsom vilka symptom patienterna hade kan tala för att 
äldre patienter kan ha sin tumör på mer svåropererade platser. Sammanfattningsvis så har 
äldre patienter annorlunda tumörer och på grund av detta erbjuds äldre annorlunda behandling 
då det anses inte kunna dra nytta av för aggressiv behandling. 
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13. Appendices 
13.1 Case report form 
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13.2 Flow-chart detailing exclusion process 
 
192 patients identified with histopathological 
diagnosis of grade II or grade III glioma 
Infratentorial glioma 
(n=6) 
Medical records not 
accessible  
(n=2) 
Glioma with a typical MRI 
finding of a glioblastoma, 
i.e. sampling bias 
(n= 19) 
Other histopathology than 
astrocytoma, 
oligoastrocytoma or 
oligodendroglioma 
(n=4) 
Included patients 
(n=159) 
Previous resection 
(n =2) 
